-
ARYx Therapeutics is a privately-held, product-driven pharmaceutical company with expertise and intellectual property in the area of retrometabolic drug design. Despite rigorous pre-approval testing of pharmaceutical products, many approved drugs have serious and life-threatening side effects that go undiscovered until the products are launched and are in widespread use. ARYx makes these known therapeutic mechanisms safer by engineering out specific metabolic problems that cause toxic and dangerous side effects. Currently three drugs are in clinical development and substantial opportunities exist to continue to broaden the product pipeline. The presentation provides an overview of the ARYx business model and the products in clinical development.
